Mineralys Therapeutics Inc (MLYS)
Mineralys Therapeutics Inc. is a NASDAQ-listed common stock company in the healthcare sector focused on biopharmaceutical development. The company is working on medicines designed to address diseases associated with dysregulated aldosterone, with lorundrostat as its lead proprietary program. Lorundrostat is an orally administered, highly selective aldosterone synthase inhibitor being developed for cardiorenal conditions linked to abnormal aldosterone activity, including hypertension, chronic kidney disease, and obstructive sleep apnea. Mineralys Therapeutics was incorporated in 2019, adopted its current name in May 2020, and is headquartered in Radnor, Pennsylvania.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-MLYS
|
$27.26
|
-2.7% Downside
|
Fair
|
$48.50
|
73.1% Upside
|
Bargain
|
Fair
|
0.0%
|
November 16, 2026
|
4.5x
|
2.479 B
|
1.913 B
|
3.8%
|
75.1%
|
10.5
|
39.7%
|
